Related Experiment Video
Updated: Feb 5, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer
Yuki Nakamura1, Tetsu Kobayashi2, Yoichi Nishii1
1Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.
Background:
Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD-L1 and PD-1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD-L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD-L1 in non-small cell lung cancer (NSCLC).
Methods:
This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28-8 antibodies.
Results:
There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28-8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28-8 antibodies was observed. The immunoreactivity rate achieved with 22C3 or 28-8 antibodies significantly correlated with tumor histological type and size, but not with specimen storage time, age, gender, smoking history, clinical stage, or lymph node metastasis.
Conclusion:
In brief, the results of this study show that the time interval between tissue sampling/paraffinization and immunohistochemical analysis has no influence on the immunoreactivity rate of PD-L1 in NSCLC.
Insights
The time between collecting and testing non-small cell lung cancer (NSCLC) tissue for PD-L1 expression does not impact immunohistochemistry results. This finding supports reliable use of archival samples for predicting response to immunotherapy.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Molecular targeted therapy, including immune checkpoint inhibitors (ICIs) like anti-PD-1/PD-L1 antibodies, has significantly improved cancer patient outcomes.
- Tumor expression levels of Programmed Death-Ligand 1 (PD-L1) are crucial biomarkers for predicting response rates to ICIs.
- Standardization of PD-L1 assessment is vital for clinical decision-making in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To investigate the impact of the time interval between tumor tissue sampling/paraffinization and immunohistochemistry (IHC) on PD-L1 staining levels in NSCLC.
- To determine if archival tissue samples yield comparable PD-L1 immunoreactivity to recent samples.
- To assess the reliability of PD-L1 testing on stored NSCLC specimens for predicting immunotherapy response.
Main Methods:
- A cohort of 137 NSCLC patients was analyzed.
- Tumor tissues were stained for PD-L1 expression using 22C3 and 28-8 antibodies via immunohistochemistry.
- Immunoreactivity rates were compared between archival and recent tissue samples, and correlated with various clinicopathological factors.
Main Results:
- A significant correlation in PD-L1 immunoreactivity was observed between 22C3 and 28-8 antibody clones.
- No statistically significant difference in PD-L1 immunoreactivity was found between archival and recent NSCLC tissue samples.
- PD-L1 expression levels correlated with tumor histological type and size, but not with specimen storage time, age, gender, smoking history, clinical stage, or lymph node metastasis.
Conclusions:
- The time interval between tissue sampling/paraffinization and IHC analysis does not influence PD-L1 immunoreactivity in NSCLC.
- Archival NSCLC tissue samples are reliable for PD-L1 assessment, supporting their use in clinical practice and research.
- These findings affirm the stability of PD-L1 expression over time in stored tissues, reinforcing its utility as a predictive biomarker for immunotherapy.
More Related Videos
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
Archival Research
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Lung Capacity
Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
Related Rates